2013年 · 第52卷第05期

Platelet activation and aggregation play a key role in the pathogenesis of atherothrombosis and are a direct cause of acute coronary (coronary) syndrome (ACS). Therefore, antiplatelet therapy is used throughout the treatment of coronary heart disease. At present, commonly used oral antiplatelet drugs in clinical practice inhibit platelet activation upstream, while platelet membrane protein (GP) Ⅱb/Ⅲa inhibitor (GPI) acts in the last link of platelet aggregation and is the strongest antiplatelet drug. As a non-peptide small molecule GPI, tirofiban has accumulated a lot of clinical research evidence in patients with ACS and percutaneous coronary intervention (PCI), and has been widely used in clinical practice in China^[1,2,3]。 Since entering the clinic in 1990s, the treatment of coronary heart disease has undergone great changes, and the use of tirofiban in different clinical situations has different characteristics. At present, with the increase of the incidence of ACS and the number of PCI, more and more patients need antiplatelet therapy, and the rational use of antiplatelet drugs is of great significance. We used the following description (recommended, available, not recommended) to grade the recommended treatment.

The prevention and treatment guidelines of bronchial asthma (hereinafter referred to as asthma) at home and abroad all point out that the goal of asthma management is to achieve and maintain asthma symptom control, and adjust the treatment plan according to asthma control level in asthma management, and carry out long-term asthma management, including three basic contents: assessment, treatment and monitoring^[1,2]。 The guidelines emphasize that most asthma patients can achieve the therapeutic goal of asthma control after medication, especially when effective management is implemented^[1,2]。 The updated version of the 2009 Global Asthma Initiative (GINA), based on the original definition of asthma control, puts forward the concept of overall asthma control, and proposes to achieve current control while reducing future risks^[3]。 However, many domestic and foreign research results show that the control rate of asthma is far lower than the target of the guidelines^{[4,5,6,7,8,9]}。 Poor control of asthma seriously affects patients' daily life, work and study, resulting in repeated acute attacks, emergency medical treatment and hospitalization, lung function impairment, increased treatment cost, reduced social productive capacity and serious socio-economic burden^{[4,5,6,7,8,9]}。 Therefore, updating the concept of asthma control, improving the existing asthma management model and strengthening the treatment strategy of asthma control are of great significance to improve the overall control level of asthma. In view of this, the Asthma Group of Respiratory Disease Branch of Chinese Medical Association organized relevant domestic experts to formulate this consensus for clinical practice reference with reference to relevant guidelines and consensus, especially the important literature on asthma control published in recent years.